Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan

Diabetes Obes Metab. 2023 Aug;25(8):2419-2422. doi: 10.1111/dom.15110. Epub 2023 May 8.

Authors

J David Smeijer¹, Donald E Kohan², Dick de Zeeuw¹, Hiddo J L Heerspink¹

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.
² Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.

PMID: 37157922
DOI: 10.1111/dom.15110

No abstract available

Keywords: clinical trial; diabetic nephropathy; endothelin receptor antagonist; heart failure.

Publication types

Letter

MeSH terms

Atrasentan / therapeutic use
Biomarkers
Diabetic Nephropathies* / drug therapy
Diuretics / therapeutic use
Endothelin A Receptor Antagonists / therapeutic use
Endothelin Receptor Antagonists / therapeutic use
Heart Failure* / drug therapy
Humans
Pyrrolidines / therapeutic use

Substances

Atrasentan
Endothelin Receptor Antagonists
Diuretics
Endothelin A Receptor Antagonists
Pyrrolidines
Biomarkers